LB Pharmaceuticals Inc filed a Form 8-K with the SEC on September 15, 2026, disclosing the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer, effective September 14, 2026.

Key Highlights

  • New CMO appointed: Susan G. Kozauer, M.D., age 54, was appointed Chief Medical Officer effective September 14, 2026.
  • Annual base salary: Dr. Kozauer is entitled to an initial annual base salary of $515,000.
  • Sign-on bonus: A one-time cash sign-on bonus of $150,000 is payable in a lump sum within 30 days following the start date.
  • Equity grant: Subject to Board approval, Dr. Kozauer will receive an option to purchase 200,000 shares of common stock, vesting over four years.
  • Annual bonus target: Dr. Kozauer is eligible for an annual discretionary bonus with a target amount equal to 40% of her annual base salary.
  • Prior experience: Dr. Kozauer most recently served as Senior Vice President, Head of Clinical Development at Centessa Pharmaceuticals from August 2025 to September 2026.
  • Severance provisions: Upon qualifying termination without cause or resignation for good reason outside a change-of-control period, Dr. Kozauer is entitled to nine months of continued base salary and up to nine months of COBRA premium reimbursement.

LB Pharmaceuticals Discloses CMO Compensation Terms and Background

According to the filing, LB Pharmaceuticals Inc (NASDAQ:LBRX) announced on September 15, 2026 that Dr. Susan G. Kozauer has joined the company as Chief Medical Officer. Before her most recent role at Centessa Pharmaceuticals, the filing states she served as Vice President in Clinical Development at Intra-Cellular Therapies, Inc. from November 2017 to August 2025. Earlier in her career, she held positions at Premier Research International LLC and Quintiles. The filing notes she holds a BA from Cornell University, a medical degree from the George Washington University School of Medicine and Health Sciences, and completed a psychiatry residency at Georgetown University Medical Center.

The company disclosed that the stock option grant of 200,000 shares will vest with 25% on the first anniversary of the start date and the remaining shares vesting monthly thereafter, subject to continued service. The option is to be granted as "an inducement material to Dr. Kozauer entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)," according to the filing. The Employment Agreement describes her employment as "at will." The filing also states that the sign-on bonus vests at 50% on each of the first and second anniversaries of the start date, and any unearned portion must be repaid if employment terminates before the second anniversary.

In the event of a qualifying termination within three months before or 12 months following a change of control, the filing discloses that Dr. Kozauer would be entitled to a lump sum equal to one year of her annual base salary plus 150% of her target bonus for the year of termination, reimbursement of COBRA premiums for up to 12 months, and acceleration of all unvested and outstanding equity awards. The company also stated it will enter into its standard indemnification agreement with Dr. Kozauer. The filing notes the full Employment Agreement will be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026.

What Was Disclosed

LB Pharmaceuticals filed an 8-K on September 15, 2026 reporting the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer effective September 14, 2026, along with key terms of her employment agreement including salary, bonus, equity grant, and severance provisions.